| Summary of Segment's Financial Information |
The following table summarizes the segment's financial information including the Company's significant segment expenses:
|
|
|
|
|
|
|
|
|
|
|
April 30, |
|
|
April 30, |
|
|
|
2025 |
|
|
2024 |
|
|
|
|
|
|
|
|
Gross Margin |
|
$ |
2,470 |
|
|
$ |
12,519 |
|
Segment operating expenses: |
|
|
|
|
|
|
Clinical and regulatory |
|
|
756,189 |
|
|
|
721,428 |
|
Research and development |
|
|
3,456,312 |
|
|
|
1,994,173 |
|
Sales and marketing |
|
|
350,167 |
|
|
|
539,682 |
|
Operations |
|
|
173,604 |
|
|
|
162,953 |
|
General and administrative |
|
|
3,618,769 |
|
|
|
2,900,053 |
|
Loss from operations |
|
|
(8,352,571 |
) |
|
|
(6,305,770 |
) |
Interest expense |
|
|
500,453 |
|
|
|
354,080 |
|
Other income |
|
|
(87,795 |
) |
|
|
(54,642 |
) |
Total other expense |
|
|
412,658 |
|
|
|
299,438 |
|
Net loss |
|
$ |
(8,765,229 |
) |
|
$ |
(6,605,208 |
) |
|